The study, published in Frontiers in Neuroscience, focused on the hypothalamic paraventricular nucleus, or PVN, a tiny cluster of neurons that acts as the brain’s master control center for the autonomic nervous system. The PVN regulates sympathetic outflow, the branch of the nervous system that raises heart rate and constricts blood vessels. In chronic hypertension, the PVN becomes dysfunctional: it pumps out excessive sympathetic drive, harbors local neuroinflammation, and runs a dysregulated renin–angiotensin system, the hormonal cascade that constricts vessels and promotes cardiac growth. This brain–heart crosstalk is what the researchers set out to modulate with needles.

The experiment used twenty-seven spontaneously hypertensive rats, a well-established genetic model of human essential hypertension, alongside nine normotensive Wistar-Kyoto controls. The hypertensive animals were randomly divided into three groups of nine: an untreated model group, an acupuncture group, and a losartan group receiving the standard antihypertensive drug at 20 milligrams per kilogram per day. The acupuncture protocol targeted three classical points, Taichong (LR3) on the foot, Baihui (GV20) on the crown of the head, and Sanyinjiao (SP6) on the lower leg, with sterile stainless-steel needles inserted 1 to 2 millimeters and manipulated by twirling for one minute per point. Treatments were delivered five mornings a week for twelve consecutive weeks, with model and control animals undergoing identical restraint handling to control for stress.

Blood pressure tracked by tail-cuff measurement told a clear story. Losartan lowered systolic and diastolic pressure significantly from week two onward, while acupuncture’s effect emerged at week four and then accumulated steadily. By week six, both interventions had produced marked, sustained reductions, and by week twelve losartan retained a modest edge in magnitude. Crucially, plasma norepinephrine, the chemical signature of sympathetic overactivation, fell significantly in both treated groups, indicating that the needles were not merely dilating vessels locally but damping the sympathetic fire originating in the brain.

The molecular heart of the study lies in the SIRT1/NF-κB/MAPK axis. SIRT1 is an NAD+-dependent deacetylase, a cellular housekeeping enzyme that deacetylates the NF-κB p65 subunit, thereby silencing the transcription factor that drives pro-inflammatory cytokine production. SIRT1 also restrains the mitogen-activated protein kinase pathways, including JNK, p38, and ERK1/2, which propagate stress and inflammatory signals. In the hypertensive rats, Western blotting of microdissected PVN tissue revealed depressed SIRT1 protein alongside elevated NF-κB p65 and phosphorylated MAPK species. Both acupuncture and losartan restored SIRT1 and suppressed the inflammatory signaling cascade, with losartan producing somewhat larger changes in this particular axis. Immunohistochemistry confirmed the pattern visually, showing more SIRT1-positive and fewer NF-κB p65-positive cells after treatment.

Downstream of this axis, the researchers measured the brain’s own renin–angiotensin system. Quantitative PCR showed that mRNA for angiotensin-converting enzyme (ACE) and the angiotensin II type 1 receptor (AT1R) were significantly upregulated in the PVN of untreated hypertensive rats, and both interventions brought these levels down to a comparable degree. This is notable because losartan is itself an AT1R blocker, yet acupuncture achieved similar suppression of the central RAS machinery, suggesting the needles engage the same hormonal circuitry through a neural route rather than a pharmacological one.

Neurotransmitter balance in the PVN also shifted. The hypertensive animals showed depleted GABA, the brain’s principal inhibitory transmitter, and elevated glutamate, its chief excitatory counterpart, a combination that biases the PVN toward heightened sympathetic output. Both treatments raised GABA and lowered glutamate, with no significant difference between the needle and drug groups. Pro-inflammatory markers told a similar story: serum IL-6 and IL-1β fell, and PVN mRNA for TNF-α, IL-1β, IL-6, and MCP-1 dropped markedly after either intervention.

The cardiac payoff was documented with echocardiography and histology. Untreated hypertensive rats displayed thickened left ventricular posterior walls and interventricular septa, reduced internal chamber diameter, and depressed ejection fraction, all hallmarks of maladaptive remodeling. Heart weight index and left ventricular mass index were elevated, and the hypertrophy markers ANP and BNP were upregulated in cardiac tissue. After twelve weeks, both acupuncture and losartan reduced wall thickness, improved chamber dimensions and ejection fraction, lowered the hypertrophy markers, and, on Masson-stained sections, shrank the blue collagen deposits that signal interstitial fibrosis. Losartan produced a slightly greater reduction in left ventricular mass index, but the two treatments were otherwise largely comparable in preserving cardiac structure and function.

The authors are careful about what the data do and do not prove. Because the study did not include PVN-targeted SIRT1 knockdown or overexpression, the causal role of SIRT1 remains associative rather than established. Blood pressure was measured by tail-cuff rather than radiotelemetry, so beat-to-beat dynamics could not be captured, and the absence of a non-acupoint sham control leaves open whether the effects are specific to the chosen points or reflect nonspecific needling and handling. Hypertension also involves interconnected brain regions beyond the PVN, and the contribution of these networks awaits exploration.

Even with those caveats, the findings carry weight. They suggest that a non-pharmacological intervention can engage the same central autonomic and inflammatory circuitry targeted by a first-line antihypertensive drug, restoring a deacetylase-driven brake on neuroinflammation within the brain’s sympathetic command center. If the mechanism translates to humans, acupuncture could serve as a complementary strategy for protecting the hypertensive heart, not by replacing medication but by working through the brain to quiet the signals that drive the muscle beneath it to overgrow.

Subject of Research: Central neural mechanisms of acupuncture-mediated cardioprotection in hypertension via the PVN SIRT1/NF-κB/MAPK signaling axis

Article Title: Acupuncture attenuates hypertension-induced myocardial hypertrophy: role of the SIRT1/NF-κ B/MAPK signaling axis in the hypothalamic paraventricular nucleus

Article References: Zhang, J., Wu, J., Wang, P., Wang, B., Li, S., Luo, G., Xiao, Z., & Liu, Q. (2026). Acupuncture attenuates hypertension-induced myocardial hypertrophy: role of the SIRT1/NF-κ B/MAPK signaling axis in the hypothalamic paraventricular nucleus. Frontiers in Neuroscience, 20, Article 1982426. https://doi.org/10.3389/fnins.2026.1982426

Image Credits: AI Generated

DOI: 10.3389/fnins.2026.1982426

Keywords: acupuncture, hypertension, myocardial hypertrophy, paraventricular nucleus, SIRT1, NF-κB, MAPK, neuroinflammation, renin-angiotensin system, sympathetic nervous system, attenuates, hypertension-induced

The review begins with a striking observation about the structure of long COVID itself. Rather than arising from a single defect, the condition appears to involve a self-reinforcing triad of persistent low-grade inflammation, autonomic nervous system imbalance, and metabolic dysfunction. Patients commonly show sustained elevation of inflammatory cytokines such as IL-6, TNF-α, and IL-1β, driven in part by lingering viral antigens, tissue injury, and macrophages locked in a pro-inflammatory state. At the same time, heart rate variability studies reveal a shift toward sympathetic dominance and reduced parasympathetic tone, while immune cells undergo a metabolic switch from efficient oxidative phosphorylation to aerobic glycolysis, depleting ATP, accumulating lactate, and damaging mitochondria through excess reactive oxygen species. Each abnormality amplifies the others, creating a vicious cycle that the authors describe as an inflammation–autonomic–metabolic pathological triad.

At the center of this cycle, the review places the vagus nerve and its cholinergic anti-inflammatory pathway, often abbreviated CAP. The vagus nerve, the tenth cranial nerve, maintains a constant dialogue between the brain and the visceral organs, with roughly 80 percent of its fibers carrying sensory information upward and the remainder delivering regulatory commands downward. When inflammatory signals reach the brainstem’s nucleus tractus solitarius, a reflex arc triggers efferent vagal output that releases acetylcholine onto immune cells in organs such as the spleen and liver. Acetylcholine binds to α7 nicotinic acetylcholine receptors on macrophages, activating a JAK2–STAT3 signaling cascade that suppresses NF-κB, inhibits assembly of the NLRP3 inflammasome, and thereby curtails production of TNF-α, IL-6, and IL-1β. In parallel, the same receptor signaling promotes Nrf2-dependent antioxidant defenses, inducing enzymes such as heme oxygenase-1 and superoxide dismutase.

Crucially, the review argues that the CAP is more than an anti-inflammatory reflex. Cholinergic signaling cross-talks with the AMPK–SIRT1–PGC-1α axis, a trio of metabolic regulators that governs mitochondrial biogenesis, antioxidant capacity, and energy homeostasis. Acetylcholine can enhance AMPK phosphorylation through calcium-dependent mechanisms, while SIRT1 activates PGC-1α by deacetylation, boosting the production of new mitochondria and improving oxidative metabolism. This coupling means that a single neural pathway could, in principle, simultaneously dampen inflammation and rebuild cellular energy supply—precisely the two functions that appear deranged in long COVID. The authors describe the CAP as a regulatory hub where neural, immune, and metabolic control converge, rather than a one-dimensional brake on cytokines.

Building on this anatomy, the review proposes that many long COVID patients may exhibit what it calls CAP hyporesponsiveness—a provisional research descriptor, not a diagnosis—characterized by reduced vagal tone, diminished acetylcholine availability, downregulated α7nAChR expression, and consequently weakened anti-inflammatory feedback. The authors are explicit that heart rate variability reduction alone cannot establish this pattern, since HRV is an indirect and non-specific marker. Instead, they outline candidate mechanistic domains spanning autonomic regulation, cholinergic signaling, inflammatory pathway activation, systemic inflammatory burden, and metabolic-mitochondrial stress, all of which would need to be measured together in prospective studies before the concept could be validated or translated into clinical subtyping.

The strongest evidence that electroacupuncture can engage this pathway comes from animal studies, and the review grades that evidence carefully. In mouse models of sepsis-related lung injury, postoperative ileus, and acute pancreatitis, stimulation at the Zusanli acupoint (ST36) on the lower leg restored α7nAChR expression, inhibited NF-κB signaling, and reduced inflammatory cytokines—and, critically, these protective effects were abolished when researchers cut the vagus nerve or blocked the α7nAChR receptor with antagonists such as methyllycaconitine. Such pathway-disruption experiments provide direct evidence that the vagal–cholinergic axis mediates at least some of electroacupuncture’s anti-inflammatory effects. Other animal work, including studies in diabetic rats, shows that electroacupuncture increases AMPK, PGC-1α, and GLUT4 expression and raises skeletal muscle ATP, supporting the metabolic arm of the proposed framework, though these findings do not by themselves prove CAP involvement.

Human evidence is more indirect but broadly consistent. Clinical studies in healthy volunteers and patients with inflammatory conditions report that electroacupuncture alters heart rate variability in a frequency-dependent manner, increases high-frequency vagal components, reduces sympathetic stress indices, and lowers circulating TNF-α and IL-1β in conditions such as knee osteoarthritis. Functional neuroimaging shows that stimulation at ST36 modulates brain regions involved in somatosensory, limbic, and autonomic processing, and small clinical reports in long COVID patients describe improvements in fatigue, dyspnea, abnormal heart rate, and inflammatory markers alongside enhanced HRV. Because no human study has directly tested CAP dependence through pathway disruption, the authors classify all clinical findings as supportive rather than conclusive, a distinction they maintain throughout the review.

To organize these heterogeneous results, the authors propose an integrated EA–CAP–AMPK–SIRT1–PGC-1α model, in which electroacupuncture stimulation enhances vagal afferent input, activates central autonomic integration in the brainstem, releases acetylcholine onto α7nAChR-expressing immune cells, and thereby suppresses NF-κB and NLRP3 signaling while simultaneously supporting mitochondrial function through the metabolic axis. They supplement this with a Neural Resonance Modulation hypothesis, suggesting that frequency-specific somatosensory input may synchronize rhythmic activity within brainstem–hypothalamic circuits, and with a neuro–immune–metabolic loop framework describing how anti-inflammatory, metabolic, and central integrative processes reinforce one another. The model explicitly distinguishes directly supported links from inferred connections and clinical extrapolations, marking the proposed convergence between CAP signaling and metabolic recovery as biologically plausible but not yet experimentally confirmed.

Looking toward translation, the review outlines phenotype-oriented strategies for future trials, proposing candidate long COVID subgroups—an autonomic-dominant type defined by abnormal HRV and orthostatic intolerance, an inflammatory-immune type marked by elevated CRP and cytokines, a metabolic-mitochondrial type dominated by fatigue and exercise intolerance, and a mixed type—each with tailored acupoints, stimulation frequencies, and outcome measures. Low-frequency stimulation of two to fifteen hertz for twenty to thirty minutes, two to three times weekly, remains the most commonly used protocol. A randomized, sham-controlled trial protocol recently designed to test electroacupuncture for long COVID neuropsychiatric symptoms in 150 patients over 16 weeks may provide the first rigorous test, though results remain pending.

The authors acknowledge substantial obstacles: stimulation parameters and acupoint combinations vary widely across studies, indirect markers such as HRV lack specificity, and mechanistic research has typically examined single pathways rather than the multi-layered coupling their framework proposes. Progress, they argue, will require CAP-centered assessment systems that combine heart rate variability, immunomics, metabolomics, and functional neuroimaging, together with phenotype-stratified randomized trials and, eventually, AI-assisted closed-loop devices that adjust stimulation in real time based on physiological feedback. Whether electroacupuncture ultimately proves effective for long COVID remains an open question, but the review offers something the field has lacked: a structured, evidence-graded map of how a peripheral nerve intervention might plausibly reach the neural, immune, and metabolic networks that this perplexing disease disrupts.

Subject of Research: Electroacupuncture modulation of vagal cholinergic anti-inflammatory and neuro-immune-metabolic pathways in long COVID

Article Title: Integrative perspectives on electroacupuncture modulation of vagal–cholinergic and neuro–immune–metabolic regulation in long COVID

Article References: Wang, L., Hu, X., & Yan, D. (2026). Integrative perspectives on electroacupuncture modulation of vagal–cholinergic and neuro–immune–metabolic regulation in long COVID. Frontiers in Integrative Neuroscience, 20, Article 1775007. https://doi.org/10.3389/fnint.2026.1775007

Image Credits: AI Generated

DOI: 10.3389/fnint.2026.1775007

Keywords: long COVID, electroacupuncture, vagus nerve, cholinergic anti-inflammatory pathway, alpha7 nicotinic acetylcholine receptor, NF-kB, NLRP3 inflammasome, AMPK, SIRT1, PGC-1alpha, mitochondrial dysfunction, autonomic dysfunction

The research team, led by Yihong Sun and Jianxin Jia, set out to answer a question that has lingered around this traditional medicinal plant for years. Cistanche glycosides, a family of phenylethanoid-rich compounds derived from a parasitic desert flower long used in Chinese medicine, had already shown antioxidant and neuroprotective effects in earlier studies, including work suggesting they could improve cognition in sleep-deprived animals. What remained unknown was whether the compound acts through this specific signaling cascade, and, crucially, whether the pathway is truly required for the benefits rather than merely changing in parallel with them.

To find out, the researchers built a rigorous experimental system. Sixty male Sprague Dawley rats were randomly assigned to six groups of ten: a normal control group, a platform control group, a sleep deprivation model group, a group receiving 50 mg/kg of the glycosides by daily gavage, a combined control-plus-glycoside group, and a group treated with the prescription sedative estazolam as a comparator. Sleep deprivation was induced with a modified multiple platform water environment method: rats stood on small platforms in shallow water for twelve hours each day over 21 consecutive days, a setup that fragments sleep without immersing the animals and that reliably produces the hallmark cognitive consequences of chronic sleep loss.

The behavioral consequences of that regimen were stark. In the Morris water maze, a standard test of spatial learning and memory in which rats must locate a hidden platform in murky water, sleep-deprived animals took significantly longer to find the platform and, when the platform was removed on the final day, crossed the target location far less often and spent less time in the target quadrant than controls. Electroencephalogram recordings, obtained from electrodes surgically implanted in the skull and neck muscles, confirmed that the model succeeded: deprived rats showed markedly increased wake time and reduced non-REM, REM, and total sleep time. Serum analysis told a parallel biochemical story, with elevated malondialdehyde, a marker of oxidative lipid damage, alongside sharply reduced activities of the antioxidant enzymes superoxide dismutase and glutathione peroxidase.

Under the microscope, the damage extended into the hippocampus, the brain’s memory hub. Nissl staining revealed that pyramidal neurons in the CA1 region of sleep-deprived rats were disorganized, shrunken, and depleted of Nissl bodies, the dense clusters of protein-making machinery that signal healthy neurons. Transmission electron microscopy went deeper still, showing mitochondria with blurred membrane boundaries, ruptured cristae, and vacuolation, the cellular equivalent of power plants falling apart. Western blot analysis then connected these structural injuries to a molecular collapse: protein levels of SIRT1, PGC-1α, and Nrf2, along with the synaptic proteins synaptophysin, PSD-95, and the neurotrophic factor BDNF, were all significantly downregulated in the deprived hippocampus.

Glycoside treatment turned this picture around. Rats receiving the compound showed shortened escape latencies, more platform crossings, and more time in the target quadrant, and they recovered a more normal sleep architecture with increased REM and NREM proportions. Their antioxidant enzyme activities rebounded, malondialdehyde levels fell, hippocampal neurons regained their organized structure and Nissl bodies, and mitochondrial morphology improved. At the molecular level, the full signaling axis, SIRT1, PGC-1α, and Nrf2, together with synaptophysin, PSD-95, and BDNF, was significantly upregulated compared with untreated sleep-deprived animals. Notably, the glycosides performed on par with estazolam across these measures, suggesting the natural extract matches a conventional sleep drug without operating through sedation alone.

The most decisive evidence came from a second cohort of forty rats in which the researchers introduced EX527, a pharmacological inhibitor that specifically blocks SIRT1. When EX527 was co-administered with the glycosides, the protective effects vanished. Treated animals again showed prolonged escape latencies, fewer platform crossings, disordered CA1 neurons, damaged mitochondria, and suppressed expression of the pathway and synaptic proteins. Statistically, the performance of the inhibitor group was indistinguishable from that of untreated sleep-deprived rats. In other words, switching off SIRT1 abolished everything the plant compound had accomplished, providing causal proof that the SIRT1/PGC-1α/Nrf2 axis is the mechanism of action rather than a bystander.

Understanding why this matters requires a look at how the pathway works. SIRT1 is an NAD+-dependent deacetylase, a longevity-linked enzyme that senses cellular energy state and removes acetyl groups from target proteins. One of its key targets is PGC-1α, the master regulator of mitochondrial biogenesis. When SIRT1 deacetylates PGC-1α, the coactivator drives Nrf2 into the nucleus, where it switches on a battery of antioxidant genes that neutralize the free radicals accumulating in stressed neurons. Sleep deprivation suppresses this entire cascade, leaving mitochondria damaged and synapses vulnerable. The new study demonstrates that glycosides of Cistanche restore the axis from its upstream gatekeeper down to its synaptic outputs, extending earlier work showing that hydrogen sulfide can protect the hippocampus by upregulating SIRT1 in sleep-deprived animals.

The authors are candid about the study’s boundaries. Only young adult male rats were tested, leaving questions about whether the findings generalize to females or aged animals. A single dose of the extract was used, so no dose-response relationship has been established. Because glycosides of Cistanche are a multi-component botanical extract, the specific constituent responsible for SIRT1 activation remains unidentified, and more rigorous phytochemical standardization will be needed before clinical translation. The researchers also note that other mechanisms, such as direct activation of Nrf2 or anti-inflammatory actions, cannot be entirely excluded, and sleep architecture was measured only in a two-hour window after deprivation sessions.

Even with those caveats, the convergence of behavioral, histological, ultrastructural, and molecular evidence, capped by pharmacological reversal, makes a compelling case. For shift workers, students, and the billions of adults who sleep less than the recommended seven to nine hours, the prospect of a natural compound that shields the sleep-deprived brain is tantalizing. The findings do not suggest that pills can substitute for sleep, but they do identify a concrete molecular target for future neuroprotective drugs aimed at the cognitive toll of sleep disorders, and they lend modern mechanistic rigor to a desert plant that traditional medicine has prized for centuries.

Subject of Research: Neuroprotective effects of Cistanche glycosides on sleep deprivation-induced cognitive dysfunction via the SIRT1/PGC-1α/Nrf2 pathway

Article Title: Glycosides of Cistanche improve cognitive dysfunction in sleep-deprived model rats by activating the SIRT1/PGC-1α/Nrf2 signaling pathway

Article References: Li, Q., Zhao, S., Huo, J., Wang, Y., Sun, Y., & Jia, J. (2026). Glycosides of Cistanche improve cognitive dysfunction in sleep-deprived model rats by activating the SIRT1/PGC-1α/Nrf2 signaling pathway. Frontiers in Molecular Neuroscience, 19, Article 1945359. https://doi.org/10.3389/fnmol.2026.1945359

Image Credits: AI Generated

DOI: 10.3389/fnmol.2026.1945359

Keywords: sleep deprivation, Cistanche glycosides, SIRT1, PGC-1α, Nrf2, oxidative stress, hippocampus, synaptic plasticity, mitochondria, Morris water maze, EX527, neuroprotection

The numbers behind that headline conclusion deserve close inspection, because they illustrate both the promise and the pitfalls of modern evidence synthesis. For irisin, the pooled weighted mean difference was 1.84 nanograms per milliliter, with a 95 percent confidence interval stretching from minus 0.25 to 3.93 nanograms per milliliter and a p-value of 0.084. For SIRT1, the weighted mean difference was 1.57 nanograms per milliliter, with a confidence interval of minus 0.18 to 3.31 and a p-value of 0.078. In both cases the point estimates lean in a positive direction, hinting that vitamin D might nudge these biomarkers upward, but the confidence intervals cross zero, which means the observed shifts are statistically indistinguishable from random noise at the conventional threshold of significance.

What makes the null result particularly striking is the sheer biological plausibility of the hypothesis being tested. Irisin is a myokine released by skeletal muscle during exercise, originally identified as a cleaved fragment of the membrane protein FNDC5, and it has been implicated in the browning of white adipose tissue, improved insulin sensitivity, and broader metabolic remodeling. SIRT1, meanwhile, is an NAD-dependent deacetylase that senses cellular energy status and influences mitochondrial biogenesis, inflammation, and DNA repair, making it a central node in the biology of aging. Vitamin D, acting through its nuclear receptor, regulates the expression of hundreds of genes, and laboratory studies have suggested crosstalk between vitamin D signaling and both irisin production and sirtuin activity. If supplementing with the vitamin were going to meaningfully rewire human metabolism through these pathways, the trials included in this analysis should have caught at least a whisper of it.

The research team cast a wide net to make sure that whisper, if it existed, would be heard. They systematically searched Scopus, Web of Science, and PubMed from database inception through 15 June 2026, restricting inclusion to randomized controlled trials, the gold standard for causal inference in clinical research. Two reviewers independently performed data extraction and risk-of-bias assessment using the Cochrane RoB 2 tool, the current benchmark for evaluating the internal validity of randomized trials. To generate pooled effect sizes, the authors used a random-effects model, which assumes that the true effect may vary from study to study rather than assuming a single fixed value, an appropriate choice given the diversity of populations, doses, and durations across the included trials. Heterogeneity, the statistical signature of that between-study variation, was quantified with the I-squared statistic, and sensitivity and subgroup analyses were deployed to hunt down its sources.

And here is where the story gets genuinely interesting, because the heterogeneity was enormous. The I-squared value for irisin was 95.0 percent, and for SIRT1 it was 92.3 percent, figures that indicate the vast majority of the observed variance between studies reflects real differences among the trials rather than chance. In meta-analytic terms, an I-squared above 75 percent is considered substantial; values in the nineties are a loud alarm that the pooled estimate is averaging together studies that may be measuring subtly different phenomena in different people. This is precisely why the authors paired their headline result with a battery of subgroup analyses, and why they urge readers to treat the headline, not the subgroups, as the primary finding.

Those subgroup analyses did surface some provocative signals. Vitamin D supplementation was associated with a significant increase in circulating irisin among patients with type 2 diabetes mellitus, with a p-value of 0.029, and among studies conducted in Iran, with a p-value of 0.025. For SIRT1, significant increases emerged in trials lasting twelve weeks, at a p-value of 0.008, and in the subgroup receiving 7,000 international units per week, which also reached p equals 0.008. The authors are careful to flag that this last estimate rests on only a single effect size, making it exploratory at best. In other words, the tantalizing possibility that vitamin D might raise irisin in diabetics, or boost SIRT1 over a twelve-week course, cannot be ruled out, but the evidence base is too thin and too heterogeneous to support firm clinical claims.

This tension between aggregate null results and suggestive subgroup findings is a recurring theme in nutrition science, and it carries real lessons for how the public should interpret supplement research. Subgroup analyses divide already-small datasets into smaller slices, and each additional slice multiplies the risk of false positives, a statistical phenomenon related to the multiple comparisons problem. A significant p-value in one subgroup, drawn from a handful of trials, is a hypothesis generator, not a prescription. The authors of the new analysis say as much in their conclusion, noting that the subgroup findings should be interpreted cautiously because of the small number of studies, the substantial heterogeneity, and the limited evidence underlying several of the subgroup estimates. It is a refreshingly restrained stance in a field where single positive subgroups often get inflated into marketing slogans.

There is also a deeper mechanistic question lurking beneath the statistics. Circulating irisin levels are driven primarily by physical activity and muscle mass, and SIRT1 activity is tightly coupled to cellular NAD availability and energy stress, both of which respond powerfully to exercise, caloric balance, and sleep but only weakly, if at all, to passive nutrient supplementation. A hormone whose raison d’être is to signal that muscles are working may simply not respond to a pill that tells the body nothing about mechanical load. The null result, viewed through this lens, is less a disappointment than a confirmation of a growing consensus: molecules that mediate the benefits of exercise and energy restriction tend to be recruited by the actual behaviors, not by pharmacological shortcuts that mimic one input to a vastly complex system.

The practical implications are straightforward. For the general population without a diagnosed deficiency, this analysis offers no support for taking vitamin D with the expectation of raising irisin or SIRT1, and by extension no support for claims that supplementation will deliver the metabolic and anti-aging benefits those biomarkers are often invoked to represent. For people with type 2 diabetes, and for the specific dosing and duration patterns flagged in the subgroups, the door remains open for larger, better-designed trials to test whether a real effect exists in those contexts. Until such trials arrive, the burden of proof stays where the authors left it: with the hypothesis, not the supplement bottle.

What the study ultimately demonstrates is the value of rigorous, preregistered-style evidence synthesis in a supplement landscape crowded with overinterpretation. By combining only randomized controlled trials, applying the Cochrane RoB 2 tool uniformly, using random-effects models, quantifying heterogeneity honestly, and running leave-one-out sensitivity analyses to confirm that no single study was driving the pooled estimates, the research team has produced a result that is more trustworthy than any individual trial in the set. The finding that vitamin D does not significantly move circulating irisin or SIRT1 will not trend as easily as a miracle-nutrient headline, but it is exactly the kind of careful, unglamorous work that gradually separates what supplements actually do from what the wellness industry wishes they did. In the ongoing effort to understand how vitamin D interacts with the molecular machinery of metabolism and aging, this meta-analysis closes one appealing shortcut and, in doing so, points researchers back toward the harder, more promising questions of who, if anyone, might genuinely benefit.

Subject of Research: The effect of vitamin D supplementation on circulating irisin and SIRT1 biomarker levels

Article Title: No significant effect of vitamin D supplementation on circulating Irisin and SIRT1 levels: a systematic review and meta-analysis of randomized controlled trials

Article References: Amouji, H., Pam, P., Panahiyan, P., Safari, M., Hojati, A., & Moradi, S. (2026). No significant effect of vitamin D supplementation on circulating Irisin and SIRT1 levels: a systematic review and meta-analysis of randomized controlled trials. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02518-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02518-1

Keywords: vitamin D, irisin, SIRT1, meta-analysis, systematic review, randomized controlled trials, biomarkers, supplements, metabolism, type 2 diabetes, heterogeneity, endocrinology

The research team, led by Elnaz Harooni and colleagues at Ahvaz Jundishapur University of Medical Sciences in Iran, focused on a well-established experimental approach: the letrozole-induced PCOS mouse. Letrozole is a nonsteroidal inhibitor of aromatase, the enzyme encoded by the Cyp19a1 gene that converts testosterone into estrogen. By blocking estrogen production, letrozole causes androgens to accumulate in female rodents, producing a cluster of symptoms that closely mirrors human PCOS, including androgen excess, elevated blood glucose, abnormal follicle development, and oxidative stress. The researchers administered letrozole orally at 6 milligrams per kilogram of body weight for 21 consecutive days to adult female NMRI mice, then confirmed the PCOS phenotype through daily vaginal smear cytology, which revealed disrupted and arrested estrous cycles in the treated animals.

Lauric acid is a medium-chain fatty acid that accounts for roughly 45 to 53 percent of coconut oil and is widely credited with many of the oil’s reported health benefits, from improved cognitive function in Alzheimer’s disease to reduced cardiovascular risk. Previous work has shown that lauric acid can lower body weight, improve lipid profiles, and enhance insulin sensitivity, effects that have been linked to activation of the Sirt1/AMPK signaling pathway in the liver. That pathway is central to cellular energy sensing: AMP-activated protein kinase, or AMPK, monitors intracellular energy status and maintains energy homeostasis at both the cellular and whole-body levels, while sirtuin 1, or Sirt1, is an NAD-dependent histone deacetylase involved in glucose and lipid metabolism, oxidative stress regulation, and reproductive function. Notably, Sirt1 expression in the ovary is reduced in both human PCOS patients and animal models, making the Sirt1/AMPK axis an attractive therapeutic target.

In the new experiment, forty mice were divided into four groups of ten: a normal control group, a group receiving lauric acid alone, a PCOS group receiving letrozole followed by vehicle, and a PCOS group treated with lauric acid at 150 milligrams per kilogram per day for 15 days after PCOS induction. The dose was selected on the basis of prior studies demonstrating its efficacy and safety across a wide range. The results were striking in several domains. Lauric acid treatment significantly lowered fasting blood glucose and fasting insulin concentrations in the PCOS mice, and it significantly improved both the HOMA-IR index, a standard measure of insulin resistance, and the QUICKI index, which reflects insulin sensitivity. Given that compensatory hyperinsulinemia drives many PCOS features and increases the risk of cardiovascular disease and type 2 diabetes, this metabolic improvement is clinically meaningful.

The fatty acid also reshaped the hormonal landscape of the treated animals. Letrozole had produced the classic PCOS hormonal signature: elevated luteinizing hormone, an increased LH-to-FSH ratio, and raised testosterone, accompanied by reduced follicle-stimulating hormone, progesterone, and estradiol. Fifteen days of lauric acid administration significantly decreased testosterone, LH, and the LH/FSH ratio while significantly raising estradiol levels. Mechanistically, this appears to involve restoration of the aromatase machinery: lauric acid significantly reversed the letrozole-driven decline in ovarian Cyp19a1 protein expression, the very enzyme the drug inhibits, while simultaneously reducing the elevated expression of ovarian androgen receptors that had heightened the animals’ sensitivity to accumulated androgens. Progesterone levels, however, remained depressed despite treatment, a limitation the authors openly acknowledge.

Lipid metabolism responded robustly as well. PCOS mice showed markedly elevated triglycerides and LDL cholesterol alongside reduced HDL cholesterol, a dyslipidemic pattern that mirrors the cardiovascular risk profile of human patients. Lauric acid treatment significantly increased HDL cholesterol and reduced both LDL cholesterol and triglycerides, and it significantly lowered the atherogenic index, a logarithmic marker of cardiometabolic risk calculated from the triglyceride-to-HDL ratio. Interestingly, lauric acid improved this index even in healthy mice, suggesting the fatty acid may beneficially modulate lipid handling independent of disease state. Consistent with these findings, the expression of two key adipose tissue regulators, adiponectin and peroxisome proliferator-activated receptor gamma, or PPARγ, was sharply reduced in the white adipose tissue of PCOS mice and significantly restored by lauric acid treatment. These molecules cooperate in regulating glucose and lipid homeostasis, and their upregulation may partially explain the observed improvements in insulin sensitivity.

The study also probed the oxidative and structural consequences of the disease. Ovaries from PCOS mice contained significantly higher concentrations of malondialdehyde, a lipid peroxidation product, and significantly lower total antioxidant capacity, reflecting the oxidant-antioxidant imbalance known to impair oocyte maturation, ovulation, and fertilization. Lauric acid treatment shifted both markers back toward normal. Histological examination told a parallel story: letrozole produced large ovarian cysts and drastically reduced the number of healthy and antral follicles, whereas lauric acid-treated mice showed fewer cystic follicles and a significant recovery of antral follicle formation, indicating a partial resumption of follicular development. Western blot analysis provided the molecular capstone, revealing that lauric acid significantly restored the letrozole-suppressed expression of Sirt1 and AMPK proteins within ovarian tissue.

The authors propose that these molecular changes form a coherent mechanism. Sirt1 is known to regulate aromatase expression in granulosa cells and to protect both pancreatic beta cells and ovarian granulosa cells through antioxidant and anti-inflammatory actions, while the Sirt1/AMPK pathway has been directly implicated in the insulin resistance of PCOS. The restoration of GLP-1, a gut-derived incretin hormone that fell significantly in PCOS mice and rebounded with lauric acid treatment, adds another layer, since GLP-1 receptor agonists are increasingly used to manage PCOS and have been linked to enhanced adiponectin and PPARγ activity. Not every parameter responded, however. Body weight gain induced by letrozole was not reversed, spexin, another metabolic hormone, remained unchanged, and the improvement in estrous cyclicity, though notable, with 60 percent of treated mice showing normal cycles versus 30 percent of untreated PCOS mice, did not reach statistical significance.

As the authors emphasize, this is the first study to evaluate lauric acid in a letrozole-induced PCOS model, and the findings should be interpreted as preliminary. The work was conducted in mice over a short treatment window, and the improvements, while broad, were partial and inconsistent across all measured endpoints. Translating a 150 milligram per kilogram daily dose into a safe and effective human regimen would require extensive dose-ranging, pharmacokinetic, and safety studies, and the relationship between dietary coconut oil consumption and purified lauric acid supplementation is far from straightforward. Nevertheless, the convergence of evidence, improved insulin sensitivity, corrected dyslipidemia, partially restored sex hormones, reduced oxidative stress, healthier ovarian histology, and reactivated Sirt1/AMPK signaling, positions lauric acid as a compelling candidate for further investigation as a complementary agent against the metabolic and endocrine disturbances of PCOS. Larger and longer studies will be needed to confirm whether this humble coconut-derived fatty acid can truly deliver on that promise.

Subject of Research: Effects of lauric acid on endocrine and metabolic alterations in a letrozole-induced mouse model of polycystic ovary syndrome

Article Title: Lauric acid ameliorates endocrine-metabolic alterations in letrozole-induced polycystic ovary syndrome in female mice

Article References: Harooni, E., Ahangarpour, A., Khorsandi, L., & Mard, S. A. (2026). Lauric acid ameliorates endocrine-metabolic alterations in letrozole-induced polycystic ovary syndrome in female mice. Heliyon, 12(15), Article e45556. https://doi.org/10.1016/j.heliyon.2026.e45556

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45556

Keywords: PCOS, lauric acid, coconut oil, Sirt1, AMPK, insulin resistance, letrozole, hyperandrogenism, adiponectin, PPAR gamma, oxidative stress, mouse model

The researchers used a classic experimental strategy known as the pentylenetetrazol, or PTZ, kindling model. Kindling is a phenomenon in which repeated, subconvulsive stimulation of the brain progressively lowers the seizure threshold until full-blown seizures emerge spontaneously. It is widely regarded as one of the best laboratory approximations of how human temporal lobe epilepsy develops over months and years. In the study, thirty-two Wistar albino rats were divided into four groups. Two groups received PTZ at a dose of 35 milligrams per kilogram of body weight three days per week to induce kindling, while the control groups received equivalent volumes of saline. Half of the animals in each condition were also given resveratrol at 5 milligrams per kilogram per day by intraperitoneal injection for twenty-eight days. Twenty-four hours after the final injection, the team harvested brain tissue for a battery of molecular and histological analyses.

The behavioral and electrophysiological results were striking. Rats that received resveratrol alongside PTZ showed a dramatically longer delay before their first myoclonic jerk, the sudden muscle twitch that marks the earliest observable seizure manifestation, with the difference reaching a p-value of 0.0001. The treated animals also spent less time in the full seizure phase and displayed a markedly lower total spike count on electrocorticography, the technique of recording electrical activity directly from the surface of the brain. In practical terms, the polyphenol did not merely soften the symptoms of an already kindled brain; it slowed the kindling process itself, pushing back the point at which the animals’ neural circuits tipped into pathological synchrony.

Under the microscope, the protection was visible in the hippocampal CA1 region, a subfield of the hippocampus that is exquisitely vulnerable to seizure-driven damage and is a hallmark site of neuron loss in human epilepsy. Hematoxylin and eosin staining, the workhorse technique of histology that highlights cell nuclei and tissue architecture, revealed that PTZ-kindled rats suffered clear neuronal deterioration and inflammation in CA1. In the animals that also received resveratrol, tissue integrity was substantially preserved, with fewer signs of neuronal injury and a calmer inflammatory landscape. Because the hippocampus is central to memory formation as well as seizure generation, preserving its cellular architecture has implications that extend beyond seizure control to the cognitive decline that often accompanies chronic epilepsy.

To understand the mechanism, the team turned to sirtuin 1, or SIRT1, a NAD-dependent deacetylase enzyme that has become one of the most intensively studied stress-response regulators in biology. SIRT1 sits at the intersection of metabolism, inflammation, and cell survival, and resveratrol has long been described as one of its pharmacological activators. Immunofluorescence staining showed that PTZ kindling depleted SIRT1 levels in the hippocampus, consistent with the idea that repeated seizures overwhelm the brain’s endogenous protective machinery. Resveratrol treatment restored SIRT1 to near-normal levels, suggesting that the compound re-engages a cellular stress-response program that epilepsy had switched off.

At the same time, resveratrol suppressed the molecular signature of programmed cell death. Immunofluorescence revealed that PTZ elevated caspase-3, the central executioner enzyme of apoptosis, along with S100B, a protein released by glial cells that serves as a widely used biomarker of astrocyte activation and brain injury. Both markers fell significantly in the resveratrol-treated animals. Quantitative polymerase chain reaction confirmed the pattern at the transcript level: expression of caspase-3 and caspase-9, the initiator caspase that feeds into the executioner cascade, were both downregulated by resveratrol, while SIRT1 messenger RNA rose. Together, these data sketch a coherent pathway in which resveratrol activates SIRT1, and SIRT1 in turn restrains the apoptotic and glial responses that would otherwise dismantle hippocampal circuitry during epileptogenesis.

Perhaps the most novel finding concerns ion channels. The researchers measured the expression of three genes that directly govern the electrical behavior of neurons: SERCA2a, the sarco/endoplasmic reticulum calcium ATPase 2a, which pumps calcium back into intracellular stores and is essential for terminating calcium signals; CACNA1G, which encodes the alpha-1G subunit of T-type voltage-gated calcium channels, a channel family notorious for driving the rhythmic burst firing that underlies absence seizures and thalamocortical oscillations; and HCN2, a hyperpolarization-activated cyclic nucleotide-gated channel subunit that carries the current responsible for a neuron’s resting pacemaker activity. PTZ kindling disrupted the expression of all three. Resveratrol reversed those changes, significantly upregulating SERCA2a, CACNA1G, HCN2, and SIRT1 with p-values below 0.0001.

The significance of this ion channel result is hard to overstate. Intracellular calcium is the master currency of neuronal signaling, and its mishandling is a recurring theme in epilepsy, stroke, and neurodegenerative disease. Excess calcium triggers excitotoxicity, the process by which overstimulated neurons literally digest themselves, and it feeds forward into mitochondrial stress and apoptosis. By restoring SERCA2a, resveratrol appears to strengthen the cell’s ability to clear calcium from the cytoplasm, while the coordinated changes in CACNA1G and HCN2 suggest a recalibration of the channels that set neuronal firing thresholds. The authors describe this as the first in vivo evidence that resveratrol modulates these specific ion channel genes to control calcium balance and excitability during epileptogenesis, a claim that, if replicated, positions the polyphenol as something closer to a circuit-level neuromodulator than a generic antioxidant.

Several caveats deserve emphasis. The study was conducted in a rodent model with intraperitoneal dosing, and the dose used, 5 milligrams per kilogram per day, does not translate directly to human supplementation, particularly given resveratrol’s notoriously poor oral bioavailability. The kindling model captures certain features of acquired epilepsy but not others, and the paper reports results from a relatively small sample of thirty-two animals. The article was also shared early as an accepted, citable version subject to further editorial processing. None of this diminishes the internal consistency of the data, which align behavioral, electrophysiological, histological, protein-level, and transcript-level evidence around a single mechanistic story, but it does mean that clinical relevance remains a hypothesis rather than a conclusion.

Even so, the study lands at a moment of genuine unmet need. Roughly a third of people with epilepsy are resistant to existing antiseizure medications, which largely work by suppressing neuronal firing rather than by modifying the disease process itself. A compound that appears to act on epileptogenesis, the slow remodeling of brain circuits that turns a healthy brain into an epileptic one, rather than merely damping acute seizures, would represent a fundamentally different therapeutic strategy. Resveratrol’s safety profile in humans is comparatively well characterized, and its ability to cross the blood-brain barrier has been documented in prior work. The present findings do not justify self-treatment, and the authors themselves frame the work as mechanistic rather than clinical. But they do give researchers a concrete molecular target list, SIRT1, SERCA2a, CACNA1G, HCN2, and the caspase cascade, around which to design the next generation of neuroprotective experiments, whether those involve resveratrol itself, more potent SIRT1 activators, or drugs aimed directly at the calcium-handling machinery of the epileptic hippocampus.

Subject of Research: Neuroprotective effects of resveratrol on the hippocampus in a PTZ-kindling model of epilepsy

Article Title: The effect of resveratrol on the hippocampus in the pentylenetetrazol (PTZ) – dependent kindling model of epilepsy

Article References: Unal, O., Akgun-Unal, N., Tiryaki, E. S., Gulbahce-Mutlu, E., Simsek, S., & Dasdelen, D. (2026). The effect of resveratrol on the hippocampus in the pentylenetetrazol (PTZ) – dependent kindling model of epilepsy. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05638-2

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05638-2

Keywords: resveratrol, epilepsy, hippocampus, SIRT1, PTZ kindling, ion channels, apoptosis, SERCA2a, CACNA1G, HCN2, neuroprotection, calcium signaling

MicroRNAs are tiny single-stranded RNA molecules, roughly twenty-two nucleotides long, that act as post-transcriptional brakes on gene expression. By binding to messenger RNAs, a single microRNA can simultaneously dampen dozens of target genes, which makes them powerful coordinators of cellular programs. The miR-34 family, which includes miR-34a and miR-34c, is positively regulated by the tumor suppressor p53 and is well established as a metastasis-suppressing force in many cancers, including adult glioblastoma. Because pediatric high-grade gliomas frequently harbor inactivating mutations in the TP53 gene, the researchers suspected that the miR-34 axis might be crippled in these tumors—but until now, its role had never been examined.

The team worked with two cell line models derived from molecularly distinct patients. SF188 came from a biopsy of an eight-year-old boy, while KNS42 was established from an aggressive tumor resected from a sixteen-year-old male and carries the distinctive H3F3A G34V histone mutation. Both lines express glial markers and harbor point mutations in p53. Using quantitative PCR, the researchers found that both miR-34a and miR-34c were significantly downregulated in the tumor cell lines compared with normal human astrocytes. They then turned to a public tumor dataset, GEO accession GSE63319, comprising eleven pHGG-4 cases and four age-matched controls, and found that mean miR-34c expression was markedly reduced in the patient tumors, while miR-34a was low in a subset of samples.

With the suppressors confirmed to be missing, the researchers reintroduced them. They transfected the cells with synthetic miR-34a or miR-34c mimics, or with a scrambled oligonucleotide as a negative control, and measured the consequences. The results were striking. Ectopic upregulation of either microRNA reduced cell viability by roughly forty percent in KNS42 cells and sixty percent in SF188 cells. Colony formation assays, in which single cells must proliferate into visible colonies of at least fifty cells over several weeks, told the same story: colony formation fell by 63 to 69 percent in KNS42 cells and by 54 to 62 percent in SF188 cells, depending on which microRNA was restored.

The most clinically meaningful effects concerned the tumor’s infiltrative behavior, the property that makes complete surgical removal nearly impossible. In scratch wound healing assays, restoring miR-34a or miR-34c inhibited gap closure in SF188 cells by 29 and 46 percent respectively. In transwell migration assays, miR-34a slashed KNS42 cell migration by 73 percent, while miR-34c cut it by 42 percent. Invasion through a basement membrane extract was similarly blunted: miR-34a reduced invasiveness by 56 percent in SF188 and 57 percent in KNS42 cells, and miR-34c by 43 and 46 percent. In other words, both microRNAs acted as broad brakes on the very behaviors that drive tumor spread through a child’s brain.

To understand how these small RNAs achieved such wide-ranging effects, the team mapped their impact on the molecular machinery of survival and proliferation. Both microRNAs downregulated the anti-apoptotic gene BCL-2 and upregulated the pro-apoptotic genes PUMA and, in some cases, BAX and BIM, while inducing the cell cycle arrest gene P21. They also suppressed CDK6, a driver of cell cycle progression, and reduced the potent oncogenes N-MYC and C-MYC, though in a pattern that differed between the two microRNAs and the two cell lines. Notably, these targeting patterns diverged from those previously reported in other cancers, underscoring that the miR-34 family operates through non-redundant, context-dependent pathways in pediatric glioma cells.

Perhaps the most surprising finding involved p53 itself. Although both cell lines carry point mutations in TP53, immunofluorescence staining with conformation-specific antibodies revealed that the mutant protein predominantly adopts a mutant shape in untreated cells—and that restoring either miR-34a or miR-34c shifted the protein toward its wild-type conformation in both cell lines. This conformational rescue was accompanied by a sharp drop in SIRT1, an NAD-dependent deacetylase that normally restrains p53 activation. SIRT1 mRNA was three to 3.6-fold elevated in the tumor cells relative to normal astrocytes, and both microRNAs cut its mRNA levels by roughly half while reducing protein expression by 50 to 85 percent. Together, these changes suggest that the miR-34 family can partially reactivate the cell’s central tumor-suppressive circuitry even in tumors where the guardian gene itself is mutated.

The researchers then probed the epithelial–mesenchymal transition, or EMT, the cellular program by which tumor cells lose adhesion and polarity and gain migratory, invasive, and stem-like properties. In central nervous system tumors, EMT-like mechanisms mirror those of epithelial cancers and are thought to underpin much of pHGG-4 aggressiveness. Both microRNAs targeted multiple EMT mediators, including the NOTCH1 and NOTCH2 receptors, the transcriptional repressor SNAIL1, the interleukin-6 receptor and its downstream effector STAT3, and the receptor tyrosine kinase C-MET, whose expression fell by up to 80 percent at the mRNA level. The team also detected nMET, a truncated nuclear C-MET fragment associated with malignant progression, and found it reduced as well. Downstream, miR-34c dampened phosphorylated FAK in both cell lines, while miR-34a did so only in SF188 cells. Meanwhile, the epithelial marker CDH1, encoding E-cadherin, was restored up to four-fold in KNS42 cells, and the stemness markers CD133 and NESTIN fell by 32 to 71 percent across both models.

A recurring theme throughout the study is that the two microRNAs, while producing similar phenotypic outcomes, achieved them through overlapping but non-identical molecular routes that varied between cell lines. miR-34c emerged as the broader suppressor, hitting N-MYC, C-MYC, SIRT1, nMET, and pFAK across both models, whereas miR-34a showed a particularly strong inhibitory effect on the migratory behavior of the H3F3A G34-mutated KNS42 line. This cell line dependence reinforces the study’s central message: epigenetic dysregulation, rather than a short list of recurrent genetic alterations, is a central engine of pHGG-4 aggressiveness, and correcting it can dismantle multiple malignant programs at once.

The findings also arrive amid a cautious resurgence of interest in microRNA therapeutics. The first-in-human trial of MRX34, a liposomal miR-34a mimic tested in non-central nervous system malignancies, produced encouraging antitumor responses before being halted over immune-mediated adverse events. Challenges such as delivery to brain tissue, variable expression, and immune safety remain formidable. Still, by demonstrating that two naturally occurring tumor suppressors can simultaneously curb survival, proliferation, migration, invasion, and stemness in an otherwise untreatable pediatric cancer, this work lays a rational foundation for miR-34-based therapeutic strategies—and offers a glimmer of hope for children facing one of medicine’s most devastating diagnoses.

Subject of Research: The role of the microRNAs miR-34a and miR-34c as tumor suppressors regulating aggressiveness in pediatric high-grade glioma grade 4

Article Title: The potential role of miR-34a and miR-34c in the regulation of pediatric high-grade glioma 4 aggressiveness

Article References: Rogachevsky, D., Yalon, M., Mehrian-Shai, R., & Toren, A. (2026). The potential role of miR-34a and miR-34c in the regulation of pediatric high-grade glioma 4 aggressiveness. Pediatric Research. https://doi.org/10.1038/s41390-026-05518-y

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05518-y

Keywords: pediatric high-grade glioma, miR-34a, miR-34c, microRNA, epigenetics, p53, SIRT1, EMT, C-MET, tumor suppressor, glioblastoma, miRNA therapeutics

Schizophrenia remains one of psychiatry’s most stubborn challenges. While antipsychotic medications can dampen hallucinations and delusions, cognitive impairment, spanning problems with memory, attention, and executive function, is a core determinant of long-term disability, and existing treatments offer limited benefit for these deficits. Because schizophrenia is understood as a neurodevelopmental disorder, its roots stretch back into childhood, long before the first psychotic episode typically appears in late adolescence or early adulthood. That timing creates both a problem and an opportunity. The prepubertal period, the researchers argue, represents a critical window for early intervention, because the metabolic and neuroplastic abnormalities that accumulate during development may still be potentially reversible. Intervening early, before the brain’s circuits have been permanently shaped by years of dysfunction, could in principle change the course of the illness rather than merely manage its symptoms.

To test this idea, the team used what is known as a two-hit mouse model, an experimental design that mirrors the multi-layered origins of schizophrenia in humans. The first hit was maternal immune activation: pregnant mothers had their immune systems provoked, mimicking the well-documented epidemiological link between infection during pregnancy and elevated schizophrenia risk in offspring. The second hit was chronic unpredictable stress applied to the male offspring later in development, reproducing the environmental adversity that many people who go on to develop psychosis experience during childhood and adolescence. Male mice exposed to both hits received NMN at a concentration of 2 grams per liter in their drinking water, starting at postnatal day 21 and continuing through postnatal day 30. In mouse development, this corresponds to the prepubertal and juvenile phase, roughly analogous to late childhood in humans, and it is precisely the window the researchers wanted to target.

The behavioral results were the first signal that something had changed. In the Morris water maze, a classic test in which mice must learn the location of a hidden platform using spatial cues, the NMN-treated animals showed improved spatial learning compared with their untreated two-hit counterparts. In the novel object recognition test, which exploits a mouse’s natural preference for exploring things it has never seen before, the treated animals displayed enhanced exploratory and cognitive performance, suggesting better recognition memory. These were not subtle, isolated effects confined to a single task. The improvements spanned two distinct domains of cognition, spatial navigation and object memory, both of which depend heavily on the hippocampus, the seahorse-shaped structure deep in the brain that is essential for forming new memories and that has long been implicated in schizophrenia.

When the researchers looked inside the dentate gyrus, the hippocampal subregion where new neurons are born throughout life, they found a striking pattern of changes in markers of neurogenesis. Using immunofluorescence staining, they documented increased densities of radial glia-like cells, identified as cells positive for the EdU proliferation label, the stem cell marker SOX2, and the glial marker GFAP. They also saw more proliferative progenitors marked by Ki67 and DCX, the latter a protein expressed by immature newborn neurons, and ultimately more mature NeuN-positive neurons in the region. In other words, the full pipeline of adult neurogenesis, from resident stem cells through dividing progenitors to newly integrated neurons, appeared to be running at a higher level in the NMN-treated animals. Critically, these changes in neurogenesis-related markers were positively correlated with the animals’ behavioral performance, hinting that the cellular and cognitive effects might be two sides of the same coin.

The second major thread of the study concerned mitochondria, the organelles that generate most of a cell’s chemical energy. Mitochondrial dysfunction has emerged as a recurring theme in schizophrenia research, and the hippocampus, with its high energy demands, is particularly vulnerable. Using transmission electron microscopy, the team examined the ultrastructure of hippocampal mitochondria and observed patterns consistent with improved mitochondrial health in the treated mice. Biochemical assays told a parallel story: levels of ATP, the cell’s energy currency, and NAD+, the coenzyme that NMN replenishes, were higher, as was the copy number of mitochondrial DNA, a proxy for mitochondrial abundance. Citrate synthase activity, a standard enzymatic readout of mitochondrial content, and coenzyme Q10 levels, a measure of the electron transport chain’s cargo, both shifted in directions consistent with improved mitochondrial content and homeostasis. Taken together, the data suggest that NMN did not merely tweak a single metabolic parameter but appeared to restore a broader energetic equilibrium in the hippocampus.

To probe the mechanisms more directly, the researchers turned to in vitro experiments with neural stem cells cultured under neuroinflammatory conditions, which simulate the hostile, inflammation-laden environment that brain cells face in the two-hit model. Under these conditions, NMN treatment was associated with increased neural stem cell viability and reduced apoptosis, the programmed cell death that can prune away precious newborn neurons. The treatment also altered the balance of lineage commitment, changing the expression of neuronal versus glial lineage markers, a shift that could influence the composition of the cells ultimately produced. This cell-culture arm of the study allowed the team to manipulate the signaling pathway they suspected was at work, something that is far harder to do cleanly in a living brain.

That suspected pathway runs through SIRT1, an NAD+-dependent deacetylase that has become one of the most intensively studied links between cellular metabolism and longevity. In the in vitro experiments, NMN treatment was associated with increased SIRT1 expression and decreased levels of p53 acetylation, a modification that normally destabilizes the genome and promotes cell death when p53 is active. At the same time, the researchers observed increased phosphorylation of components of the PI3K/AKT/mTOR pathway, a central signaling cascade that promotes cell survival, growth, and proliferation. The decisive experiment came when the team added EX527, a pharmacological inhibitor of SIRT1, to the cultures. The protective effects of NMN were attenuated, meaning the benefits largely disappeared when SIRT1 was blocked. This loss-of-function result provides the strongest mechanistic evidence in the paper that the SIRT1–p53–PI3K/AKT/mTOR axis is the conduit through which NMN exerts its influence on neural stem cells under inflammatory stress.

The authors are appropriately measured about what their data do and do not establish. They describe their findings as experimental evidence that prepubertal NMN administration in the combined two-hit schizophrenia model is associated with concurrent improvements in neurogenesis-related markers, mitochondrial homeostasis indices, and cognitive-related behavioral performance, potentially involving the SIRT1–p53–PI3K/AKT/mTOR signaling pathway. The word associated appears deliberately throughout the abstract, and the researchers explicitly flag two open questions: whether the changes in neurogenesis-related markers are causally required for the cognitive improvement, and which component of the two-hit model, the maternal immune activation or the chronic stress, NMN primarily acts upon. These are not trivial gaps. Correlation between newborn neurons and better maze performance does not prove the former drives the latter, and knowing which developmental insult the compound counteracts would shape how such an intervention might eventually be timed and targeted in humans.

Even with those caveats, the study lands at a compelling intersection of several fast-moving fields. The longevity community has long been fascinated by NAD+ restoration, but rigorous evidence for cognitive benefits in a neurodevelopmental context is rare. The schizophrenia field has been searching for treatments that address cognition, the domain where current drugs fail most visibly, and for interventions that can be deployed during the long prodromal window before illness onset. And the broader neuroscience of critical periods suggests that the developing brain may be uniquely responsive to metabolic interventions in ways the adult brain is not. The work, supported by the National Natural Science Foundation of China and conducted under approved animal ethics protocols, is a mouse study with in vitro mechanistic support, not a clinical trial, and no one should rush to give NMN to children based on these results alone. But as a proof of concept, it makes a vivid case that the window between childhood and adolescence may be a genuine therapeutic opportunity, and that the machinery of brain repair, from stem cell niches to mitochondrial power plants, may be more amenable to intervention during development than anyone dared to hope.

Subject of Research: Effects of prepubertal nicotinamide mononucleotide administration on hippocampal neurogenesis, mitochondrial function, and cognition in a mouse model of schizophrenia

Article Title: Prepubertal NMN Administration is associated with changes in hippocampal neurogenesis-related markers and amelioration of cognitive deficits

Article References: Yang, Z.-L., Li, J.-J., Feng, Z.-Q., Guo, C., Liu, Y.-B., Shao, Y., Lv, H.-W., Wu, K., & Liu, J. (2026). Prepubertal NMN Administration is associated with changes in hippocampal neurogenesis-related markers and amelioration of cognitive deficits. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04516-2

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04516-2

Keywords: NMN, NAD+, schizophrenia, hippocampal neurogenesis, mitochondria, SIRT1, p53, PI3K/AKT/mTOR, cognitive deficits, two-hit model, maternal immune activation, neural stem cells

Synaptic plasticity is the biological substrate of learning and memory. At its core lies long-term potentiation, or LTP, a persistent strengthening of synaptic transmission that is widely studied in the hippocampus, the seahorse-shaped structure critical for forming new memories. The review situates resveratrol within the established molecular machinery of LTP: the activation of N-methyl-D-aspartate receptors, calcium influx, the recruitment of calcium/calmodulin-dependent protein kinase II, and the insertion and upregulation of AMPA receptors at the postsynaptic membrane. It also points to the signaling cascades that stabilize potentiated synapses, including the phosphoinositide 3-kinase/Akt pathway, the mammalian target of rapamycin, and the cyclic AMP response element binding protein, CREB, which drives the expression of plasticity-related genes. Disruption of any of these nodes, the authors note, can erode the synapse’s ability to encode experience.

One of the most consequential threats to that machinery is oxidative stress. The brain is exceptionally vulnerable to it: it consumes a disproportionate share of the body’s oxygen, is rich in lipids susceptible to peroxidation, and hosts neurons that are selectively sensitive to redox imbalance. When the production of reactive oxygen species outpaces the systems that eliminate them, the resulting damage can impair synaptic proteins, distort receptor signaling, and ultimately push neurons toward apoptosis, a programmed form of cell death that the body uses to maintain cellular equilibrium. The review emphasizes that reactive oxygen species are not simply toxic byproducts; at physiological levels they participate in the regulation of synaptic plasticity and memory, which means the therapeutic goal is restoration of balance rather than wholesale suppression of redox signaling.

Resveratrol enters this picture as a bidirectional modulator. According to the review, the compound can scavenge reactive oxygen species and blunt the damage inflicted by oxidative stress, thereby protecting the molecular substrates of plasticity. It also engages cellular defense systems more broadly, including the Nrf2 signaling pathway, which coordinates the transcription of antioxidant genes. In experimental models, resveratrol treatment has been shown to attenuate neuronal apoptosis after oxygen and glucose deprivation and reoxygenation by enhancing Nrf2 activation, and to protect embryonic neural stem cells from hydrogen peroxide-induced oxidative stress. These findings position the molecule as both a direct antioxidant and an indirect activator of the cell’s own protective programs.

The review gives particular attention to sirtuin 1, or SIRT1, a NAD-dependent deacetylase that resveratrol is known to activate and that has been implicated in synaptic health. In a model of developmental lead exposure, resveratrol reversed injury to hippocampal synaptic markers and countered SIRT1 inhibition, suggesting that the polyphenol can restore a key longevity-linked signaling axis in the brain. In neonatal mice with hypoxic-ischemic brain injury, resveratrol improved synaptic plasticity by alleviating neuroinflammation mediated through the SIRT1/NF-kappaB pathway. The authors also describe work showing that resveratrol upregulates AMPA receptor expression via AMP-activated protein kinase-mediated protein translation, a mechanism that directly increases the availability of the receptors responsible for fast excitatory transmission.

Beyond receptor-level effects, the review highlights resveratrol’s influence on brain-derived neurotrophic factor, BDNF, a growth factor central to the survival and maturation of dendritic spines, the tiny protrusions where excitatory synapses reside. It also examines adult hippocampal neurogenesis, the ongoing generation of new neurons in the dentate gyrus that evidence now supports in humans and that is increasingly recognized as a contributor to learning, memory, and mood regulation. Nutrition is one of the environmental factors known to shape this process, and the review frames resveratrol as a potential hippocampal plasticity enhancer capable of supporting both the birth of new neurons and the functional integration of existing circuits.

The translational implications extend across a striking range of disease models. In rats subjected to chronic cerebral hypoperfusion, resveratrol reversed deficits in synaptic plasticity and prevented cognitive impairment. In an Alzheimer’s-relevant model, it ameliorated spatial learning and memory impairment induced by amyloid-beta(1-42). In streptozotocin-induced diabetic rats, it improved cognitive performance by regulating both apoptosis and synaptic plasticity. The review further cites work showing that resveratrol modulates cocaine-induced inhibitory synaptic plasticity in dopamine neurons of the ventral tegmental area by inhibiting phosphodiesterases, and reports of antidepressant effects in an animal model of depression, underscoring that plasticity-related mechanisms cut across neurology and psychiatry alike.

Human evidence, though thinner, is provocative. A study of healthy older adults found that resveratrol supplementation improved memory performance and altered hippocampal functional connectivity alongside changes in glucose metabolism, hinting that the compound’s metabolic effects may underpin some of its cognitive benefits. Yet the review is candid about the obstacles. Resveratrol’s bioavailability is notoriously poor, with rapid metabolism limiting the concentrations that actually reach the brain. Dose is a critical variable: infinitesimal quantities appear beneficial for cell growth, while elevated doses can be detrimental to cell viability, a hormetic profile that complicates any simple recommendation. The literature also documents potential adverse effects, meaning that higher is emphatically not better.

The authors conclude that resveratrol’s ability to modulate signaling pathways governing cell survival, apoptosis, and synaptic plasticity gives it genuine potential to mitigate cognitive decline, particularly through enhancement of hippocampal plasticity and adult neurogenesis. But the path forward, they suggest, lies in resolving the dose-response paradox, improving delivery to the central nervous system, and validating the molecular mechanisms in rigorous clinical studies. For now, the compound remains a compelling research tool and a candidate therapeutic scaffold rather than a proven memory pill, a reminder that in neuroscience, as in the synapses themselves, the dose and the context determine everything.

Subject of Research: Resveratrol's modulation of synaptic plasticity and its therapeutic potential for cognitive decline

Article Title: Resveratrol as a modulator of synaptic plasticity: molecular mechanisms and future therapeutic perspectives

Article References: Zarifkar, A. H., & Safaei, S. (2026). Resveratrol as a modulator of synaptic plasticity: molecular mechanisms and future therapeutic perspectives. Molecular Biology Reports, 53(1), Article 1642. https://doi.org/10.1007/s11033-026-12836-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12836-1

Keywords: resveratrol, synaptic plasticity, hippocampus, oxidative stress, reactive oxygen species, long-term potentiation, SIRT1, BDNF, adult hippocampal neurogenesis, neuroprotection, CREB, NMDA receptor

The breadth of melatonin’s reported activities is striking. Beyond its sedative effect, the review catalogs antitumor, immunomodulatory, antioxidant, antihypertensive and cardioprotective actions, along with roles in regulating body weight, gastrointestinal function, reproduction and thermoregulation. Part of this versatility is chemical: melatonin crosses biological membranes freely and reaches nearly every compartment of the cell. Part of it is signaling: melatonin binds specific G-protein-coupled receptors, but it also engages intracellular pathways that govern whether a cell survives stress, divides, inflames or dies. The question the review tackles is which of these pathways best explains the hormone’s pharmacological reach, and its answer centers on SIRT1, the most intensively studied member of the mammalian sirtuin family.

SIRT1 is a nicotinamide adenine dinucleotide, or NAD+, dependent deacetylase, meaning it removes acetyl chemical groups from proteins only when the metabolic cofactor NAD+ is available. This makes the enzyme a direct sensor of cellular energy status, because NAD+ levels rise and fall with nutrient availability, fasting and metabolic strain. SIRT1 shuttles between the cytoplasm and the nucleus, where it strips acetyl groups from histones, the spools around which DNA is wound, and from a growing list of non-histone proteins including the tumor suppressor p53, the transcription factors FoxO and NF-κB, and the mitochondrial regulator PGC-1α. Through these targets, SIRT1 influences cell survival, metabolism, growth, aging and resistance to stress, which is precisely the portfolio of processes that goes wrong in chronic disease.

The review’s central claim is that melatonin can modulate SIRT1 activity, and that this modulation in turn shapes four fundamental cellular responses: inflammation, oxidative stress, apoptosis and autophagy. In inflammatory bowel disease, for example, recent work cited in the review shows that melatonin restores the intestinal mucosal barrier by activating a SIRT1-LKB1-pAMPK signaling axis. In autoimmune and sepsis models, SIRT1 deacetylates components of the NF-κB pathway and the NLRP3 inflammasome, damping the production of tumor necrosis factor alpha, interleukin-1 and other inflammatory mediators. Because NF-κB sits upstream of cyclooxygenase-2 and inducible nitric oxide synthase, a single deacetylation event can cascade into a broad suppression of the inflammatory program.

The cardiovascular evidence is among the most developed. In type 2 diabetic rats, reduced SIRT1 signaling worsens myocardial ischemia-reperfusion injury, and melatonin treatment restores protection through the enzyme. Melatonin receptor-mediated cardioprotection against ischemia-reperfusion has likewise been traced to SIRT1. In diabetic hearts, melatonin prevents Drp1-mediated mitochondrial fission, the excessive fragmentation of mitochondria that starves cardiomyocytes of energy, via the SIRT1-PGC-1α pathway, and activation of the SIRT1-PGC-1α-SIRT3 cascade protects against mitochondrial dysfunction in isoproterenol-induced myocardial injury. The chemotherapy drug doxorubicin, notorious for causing heart damage, appears less toxic when melatonin activates the Sirt1/Nrf2 pathway, inhibiting oxidative stress, pyroptosis and apoptosis. In sepsis-induced cardiac dysfunction, melatonin acts through SIRT1 to regulate both apoptosis and autophagy, including SIRT1-mediated deacetylation of beclin-1 and of the transcription factor TFEB, which orchestrates lysosomal clearance of damaged material.

The kidney tells a parallel story. Melatonin attenuates acute kidney ischemia-reperfusion injury in diabetic rats by activating the SIRT1/Nrf2/HO-1 axis, a canonical antioxidant pathway in which Nrf2, once deacetylated and stabilized, switches on heme oxygenase-1 and other detoxifying genes. In diabetic kidney disease, protection runs through SIRT1/NLRP3 signaling, curbing the inflammasome-driven inflammation that scars the filtering units of the kidney. Melatonin also prevents acute kidney injury in severely burned rats via SIRT1 activation, and in cadmium-induced proximal tubular injury it preserves mitochondrial function by blocking fission through SIRT1-PGC-1α. Perhaps most intriguingly, melatonin lowers the abundance of hypoxia-inducible factor 1α in human proximal tubular cells by preventing its deacetylation by sirtuin 1, a reminder that SIRT1’s effects are not uniformly protective but context-dependent, and that melatonin’s modulation of the enzyme can push it in either direction depending on the tissue and insult.

In the liver, the review highlights melatonin’s effects on non-alcoholic fatty liver disease, a condition now affecting a substantial share of the world’s overweight and obese population. Melatonin’s benefits in fatty liver models are linked to the microRNA-34a-5p/Sirt1 axis and to autophagy, the cellular recycling system that clears lipid droplets and damaged organelles. In hypercholesterolemic mice, melatonin’s modulation of sirtuin-1 attenuates liver injury. The enzyme also mediates protection against toxic exposures: melatonin inhibits benzo(a)pyrene-induced apoptosis in mouse liver through the miR-34a/Sirt1/autophagy pathway, and it attenuates arsenic-induced liver injury through Nrf2/HO-1, apoptosis and miR-34a/Sirt1/autophagy routes. In alcoholic liver injury, melatonin-induced SIRT1 disrupts the cereblon-YY1-CYP2E1 signaling pathway, reducing the oxidative metabolism of alcohol that generates damaging free radicals, while in sepsis-induced liver injury melatonin activates SIRT1/STAT3 signaling to rescue dysregulated gluconeogenesis.

The reproductive findings may prove the most clinically provocative. In polycystic ovary syndrome, melatonin enhances SIRT1 expression in granulosa cells to ameliorate excessive PINK1/Parkin-mediated mitophagy and to protect mitochondrial membranes through PDK1/Akt signaling, and it attenuates Drp1-driven mitochondrial fission through SIRT1 upregulation. The ROS/SIRT1/STAR axis has been identified as a target through which melatonin corrects atrazine-induced mitochondrial dysfunction and steroid disorders in granulosa cells. In oocytes, melatonin protects against chronic stress-induced meiotic defects by regulating SIRT1, and follicular fluid insufficiency of melatonin has been proposed as a reversible cause of the chromosomal abnormalities seen in oocytes of advanced maternal age. On the male side, melatonin protects mouse testes from palmitic acid-induced lipotoxicity in a SIRT1-dependent manner, ameliorates diabetic impairment of Leydig cell steroidogenic function through SIRT1 activation, and modulates SIRT1 to counter LPS-induced testicular nitro-oxidative stress and inflammation. Human trials add a translational note: melatonin supplementation improved semen parameters in men with idiopathic infertility in a triple-blind randomized placebo-controlled trial, and melatonin therapy added benefit to varicocelectomy in a double-blind trial, with epigenetic effects in a varicocele rat model mediated by silent information regulator 1.

The musculoskeletal section rounds out the picture. In osteoarthritis, melatonin exerts cytoprotective and anti-inflammatory effects in human chondrocyte cells and in rabbit models via the SIRT1 pathway, prevents cartilage matrix degradation by inhibiting NF-κB through SIRT1, and regulates chondrocyte hypertrophy and apoptosis through the Sirt1/P53/P21 axis. It also promotes sirtuin 1 expression to inhibit the IRE1α-XBP1S-CHOP branch of the unfolded protein response, reducing endoplasmic reticulum stress-mediated apoptosis in chondrocytes. In intervertebral disc degeneration, melatonin protects vertebral endplate chondrocytes against apoptosis and calcification via the Sirt1-autophagy pathway and holds promise through inhibiting M1-type macrophage polarization via SIRT1/Notch signaling. Even in cancer the relationship is bidirectional: whereas SIRT1 activation generally protects healthy tissue, melatonin’s antitumor activity in human osteosarcoma cells has been attributed to SIRT1 inhibition, underscoring that the same enzyme can be friend or foe depending on cellular context.

The authors are careful to note the limits of the evidence. Despite the breadth of preclinical data, they write that evidence regarding the role of SIRT1 in melatonin’s effects remains limited, and much of what is known comes from cell cultures and animal models rather than definitive human trials. Whether melatonin reliably activates SIRT1 in human tissues at supplement doses, and whether SIRT1 is necessary rather than merely correlated with the hormone’s benefits, will require pharmacological inhibitors, genetic models and properly powered clinical studies. Still, the synthesis is compelling in its coherence: a hormone produced by a tiny gland in the brain, acting through an NAD+-dependent enzyme that links metabolism to gene expression, appears to coordinate protective programs across organs as different as the heart, kidney, liver, ovary and joint. If future work confirms SIRT1 as the common mediator, melatonin’s humble reputation as a sleep aid may give way to something far more interesting, a cheap and safely tolerated molecule that tunes the body’s central longevity machinery.

Subject of Research: The role of the SIRT1 signaling pathway in the therapeutic effects of melatonin across disease models

Article Title: The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway

Article References: Vahidinia, Z., Behdarvandy, M., Azami Tameh, A., Barati, S., & Yasamian, A. (2026). The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway. Molecular Biology Reports, 53(1), Article 1667. https://doi.org/10.1007/s11033-026-12815-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12815-6

Keywords: melatonin, SIRT1, sirtuins, NAD+, deacetylation, oxidative stress, autophagy, apoptosis, cardioprotection, diabetic cardiomyopathy, non-alcoholic fatty liver disease, polycystic ovary syndrome